000169191 001__ 169191
000169191 005__ 20240221132057.0
000169191 0247_ $$2doi$$a10.1016/j.bbr.2022.114276
000169191 0247_ $$2pmid$$apmid:36574844
000169191 0247_ $$2ISSN$$a0166-4328
000169191 0247_ $$2ISSN$$a1872-7549
000169191 0247_ $$2altmetric$$aaltmetric:140631224
000169191 037__ $$aDZNE-2023-00070
000169191 041__ $$aEnglish
000169191 082__ $$a610
000169191 1001_ $$aFelgel-Farnholz, Viktoria$$b0
000169191 245__ $$aAdolescent raloxifene treatment in females prevents cognitive deficits in a neurodevelopmental rodent model of schizophrenia.
000169191 260__ $$aAmsterdam$$bElsevier$$c2023
000169191 3367_ $$2DRIVER$$aarticle
000169191 3367_ $$2DataCite$$aOutput Types/Journal article
000169191 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1708517999_22071
000169191 3367_ $$2BibTeX$$aARTICLE
000169191 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169191 3367_ $$00$$2EndNote$$aJournal Article
000169191 520__ $$aThe existence of sex differences in schizophrenia is a well documented phenomenon which led to the hypothesis that female sex hormones are neuroprotective and hence responsible for the more favorable disease characteristics seen in women. The current study sought to investigate the effects of estrogen-like agents administered during early adolescence on behavioral outcomes in adulthood using the neurodevelopmental maternal immune activation (MIA) rodent model of schizophrenia. Female MIA offspring were administered during the asymptomatic period of adolescence with either 17β-estradiol, raloxifene or saline and were tested in late adolescence and adulthood for schizophrenia-related behavioral performance. We report here that whereas adult female MIA offspring exhibited cognitive deficits in the form of retarded spatial learning, the administration of raloxifene during adolescence was sufficient in preventing these deficits and resulted in intact performance in the MIA group.
000169191 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000169191 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000169191 650_7 $$04F86W47BR6$$2NLM Chemicals$$aRaloxifene Hydrochloride
000169191 650_7 $$2Other$$aMorris Water Maze (MWM)
000169191 650_7 $$2Other$$aPoly I:C
000169191 650_7 $$2Other$$aPreventive hormonal treatment
000169191 650_7 $$2Other$$aRaloxifene
000169191 650_7 $$2Other$$aestradiol
000169191 650_7 $$2Other$$aschizophrenia
000169191 650_7 $$0O84C90HH2L$$2NLM Chemicals$$aPoly I-C
000169191 650_2 $$2MeSH$$aAnimals
000169191 650_2 $$2MeSH$$aHumans
000169191 650_2 $$2MeSH$$aFemale
000169191 650_2 $$2MeSH$$aMale
000169191 650_2 $$2MeSH$$aRaloxifene Hydrochloride: pharmacology
000169191 650_2 $$2MeSH$$aSchizophrenia: complications
000169191 650_2 $$2MeSH$$aSchizophrenia: drug therapy
000169191 650_2 $$2MeSH$$aRodentia
000169191 650_2 $$2MeSH$$aPoly I-C: pharmacology
000169191 650_2 $$2MeSH$$aBehavior, Animal: physiology
000169191 650_2 $$2MeSH$$aDisease Models, Animal
000169191 650_2 $$2MeSH$$aPrenatal Exposure Delayed Effects
000169191 650_2 $$2MeSH$$aCognition
000169191 7001_ $$aHlusicka, Elizabeth Barroeta$$b1
000169191 7001_ $$aEdemann-Callesen, Henriette$$b2
000169191 7001_ $$0P:(DE-2719)2810535$$aGarthe, Alexander$$b3$$udzne
000169191 7001_ $$aWinter, Christine$$b4
000169191 7001_ $$aHadar, Ravit$$b5
000169191 773__ $$0PERI:(DE-600)2013604-3$$a10.1016/j.bbr.2022.114276$$gp. 114276 -$$p114276$$tBehavioural brain research$$v441$$x0166-4328$$y2023
000169191 8564_ $$uhttps://pub.dzne.de/record/169191/files/DZNE-2023-00070_Restricted.pdf
000169191 8564_ $$uhttps://pub.dzne.de/record/169191/files/DZNE-2023-00070_Restricted.pdf?subformat=pdfa$$xpdfa
000169191 909CO $$ooai:pub.dzne.de:169191$$pVDB
000169191 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810535$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000169191 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000169191 9141_ $$y2023
000169191 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-17
000169191 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-17
000169191 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-17
000169191 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-22$$wger
000169191 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBEHAV BRAIN RES : 2022$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000169191 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000169191 9201_ $$0I:(DE-2719)1740001$$kAG Garthe$$lTechnology Platform Neurobiology of Behaviour$$x0
000169191 980__ $$ajournal
000169191 980__ $$aVDB
000169191 980__ $$aI:(DE-2719)1740001
000169191 980__ $$aUNRESTRICTED